Advertisement

Long-Term Outcomes After Coronary Stent Implantation in Patients Presenting With Versus Without Acute Myocardial Infarction (an Observation from Coronary Revascularization Demonstrating Outcome Study-Kyoto Registry Cohort-2)

      It has not been adequately addressed yet how long the excess cardiovascular event risk persists after acute myocardial infarction (AMI) compared with stable coronary artery disease. Of 10,470 consecutive patients who underwent percutaneous coronary intervention either with sirolimus-eluting stent (SES) only or with bare-metal stent (BMS) only in the Coronary Revascularization Demonstrating Outcome Study-Kyoto Registry Cohort-2, 3,710 (SES: n = 820 and BMS: n = 2,890) and 6,760 patients (SES: n = 4,258 and BMS: n = 2,502) presented with AMI (AMI group) and without AMI (non-AMI group), respectively. During the median 5-year follow-up, the excess adjusted risk of the AMI group relative to the non-AMI group for the primary outcome measure (cardiac death or myocardial infarction) was significant (hazard ratio [HR] 1.53, 95% confidence interval [CI] 1.30 to 1.80, p <0.001). However, the excess event risk was limited to the early period within 3 months. Late adjusted risk beyond 3 months was similar between the AMI and non-AMI groups (HR 1.16, 95% CI 0.95 to 1.41, p = 0.15). The higher risk of the AMI group relative to the non-AMI group for stent thrombosis (ST) was significant within 3 months (HR 3.38, 95% CI 2.04 to 5.60, p <0.001), whereas the risk for ST was not different between the 2 groups beyond 3 months (HR 1.11, 95% CI 0.65 to 1.90, p = 0.70). There were no interactions between the types of stents implanted and the risk of the AMI group relative to the non-AMI groups for all the outcome measures including ST. In conclusion, patients with AMI compared with those without AMI were associated with similar late cardiovascular event risk beyond 3 months after percutaneous coronary intervention despite their higher early risk within 3 months.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • de la Torre-Hernández J.M.
        • Alfonso F.
        • Hernández F.
        • Elizaga J.
        • Sanmartin M.
        • Pinar E.
        • Lozano I.
        • Vazquez J.M.
        • Botas J.
        • Perez de Prado A.
        • Hernández J.M.
        • Sanchis J.
        • Nodar J.M.R.
        • Gomez-Jaume A.
        • Larman M.
        • Diarte J.A.
        • Rodríguez-Collado J.
        • Rumoroso J.R.
        • Lopez-Minguez J.R.
        • Mauri J.
        Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos).
        J Am Coll Cardiol. 2008; 51: 986-990
        • Kimura T.
        • Morimoto T.
        • Nakagawa Y.
        • Kawai K.
        • Miyazaki S.
        • Muramatsu T.
        • Shiode N.
        • Namura M.
        • Sone T.
        • Oshima S.
        • Nishikawa H.
        • Hiasa Y.
        • Hayashi Y.
        • Nobuyoshi M.
        • Mitudo K.
        Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry.
        Circulation. 2012; 125: 584-591
        • O'Gara P.T.
        • Kushner F.G.
        • Ascheim D.D.
        • Casey D.E.
        • Chung M.K.
        • de Lemos J.A.
        • Ettinger S.M.
        • Fang J.C.
        • Fesmire F.M.
        • Franklin B.A.
        • Granger C.B.
        • Krumholz H.M.
        • Linderbaum J.A.
        • Morrow D.A.
        • Newby L.K.
        • Ornato J.P.
        • Ou N.
        • Radford M.J.
        • Tamis-Holland J.E.
        • Tommaso C.L.
        • Tracy C.M.
        • Woo Y.J.
        • Zhao D.X.
        • Anderson J.L.
        • Jacobs A.K.
        • Halperin J.L.
        • Albert N.M.
        • Brindis R.G.
        • Creager M.A.
        • DeMets D.
        • Guyton R.A.
        • Hochman J.S.
        • Kovacs R.J.
        • Ohman E.M.
        • Stevenson W.G.
        • Yancy C.W.
        2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2013; 127: e362-e425
        • Steg P.G.
        • James S.K.
        • Atar D.
        • Badano L.P.
        • Blömstrom-Lundqvist C.
        • Borger M.A.
        • Di Mario C.
        • Dickstein K.
        • Ducrocq G.
        • Fernandez-Aviles F.
        • Gershlick A.H.
        • Giannuzzi P.
        • Halvorsen S.
        • Huber K.
        • Juni P.
        • Kastrati A.
        • Knuuti J.
        • Lenzen M.J.
        • Mahaffey K.W.
        • Valgimigli M.
        • van't Hof A.
        • Widimsky P.
        • Zahger D.
        ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
        Eur Heart J. 2012; 33: 2569-2619
        • Yusuf S.
        • Zhao F.
        • Mehta S.R.
        • Chrolavicius S.
        • Tognoni G.
        • Fox K.K.
        Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
        N Engl J Med. 2001; 345: 494-502
        • Ridker P.M.
        • Cannon C.P.
        • Morrow D.
        • Rifai N.
        • Rose L.M.
        • McCabe C.H.
        • Pfeffer M.A.
        • Braunwald E.
        C-reactive protein levels and outcomes after statin therapy.
        N Engl J Med. 2005; 352: 20-28
        • Dargie H.J.
        Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
        Lancet. 2001; 357: 1385-1390
        • Alexander J.H.
        • Lopes R.D.
        • James S.
        • Kilaru R.
        • He Y.
        • Mohan P.
        • Bhatt D.L.
        • Goodman S.
        • Verheugt F.W.
        • Flather M.
        • Huber K.
        • Liaw D.
        • Husted S.E.
        • Lopez-Sendon J.
        • de Caterina R.
        • Jansky P.
        • Darius H.
        • Vinereanu D.
        • Cornel J.H.
        • Cools F.
        • Atar D.
        • Leiva-Pons J.L.
        • Keltai M.
        • Ogawa H.
        • Pais P.
        • Parkhomenko A.
        • Ruzyllo W.
        • Diaz R.
        • White H.
        • Ruda M.
        • Geraldes M.
        • Lawrence J.
        • Harrington R.A.
        • Wallentin L.
        Apixaban with antiplatelet therapy after acute coronary syndrome.
        N Engl J Med. 2011; 365: 699-708
        • Schwartz G.G.
        • Olsson A.G.
        • Abt M.
        • Ballantyne C.M.
        • Barter P.J.
        • Brumm J.
        • Chaitman B.R.
        • Holme I.M.
        • Kallend D.
        • Leiter L.A.
        • Leitersdorf E.
        • McMurray J.J.V.
        • Mundl H.
        • Nicholls S.J.
        • Shah P.K.
        • Tardif J.-C.
        • Wright R.S.
        Effects of dalcetrapib in patients with a recent acute coronary syndrome.
        N Engl J Med. 2012; 367: 2089-2099
        • O'Donoghue M.L.
        • Braunwald E.
        • White H.D.
        • Steen D.P.
        • Lukas M.A.
        • Tarka E.
        • Steg P.G.
        • Hochman J.S.
        • Bode C.
        • Maggioni A.P.
        • Im K.
        • Shannon J.B.
        • Davies R.Y.
        • Murphy S.A.
        • Crugnale S.E.
        • Wiviott S.D.
        • Bonaca M.P.
        • Watson D.F.
        • Weaver W.D.
        • Serruys P.W.
        • Cannon C.P.
        • Steen D.L.
        Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
        JAMA. 2014; 312: 1006-1015
        • Kimura T.
        • Morimoto T.
        • Furukawa Y.
        • Nakagawa Y.
        • Kadota K.
        • Iwabuchi M.
        • Shizuta S.
        • Shiomi H.
        • Tada T.
        • Tazaki J.
        • Kato Y.
        • Hayano M.
        • Abe M.
        • Tamura T.
        • Shirotani M.
        • Miki S.
        • Matsuda M.
        • Takahashi M.
        • Ishii K.
        • Tanaka M.
        • Aoyama T.
        • Doi O.
        • Hattori R.
        • Tatami R.
        • Suwa S.
        • Takizawa A.
        • Takatsu Y.
        • Takahashi M.
        • Kato H.
        • Takeda T.
        • Lee J.-D.
        • Nohara R.
        • Ogawa H.
        • Tei C.
        • Horie M.
        • Kambara H.
        • Fujiwara H.
        • Mitsudo K.
        • Nobuyoshi M.
        • Kita T.
        Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan.
        Cardiovasc Interv Ther. 2011; 26: 234-245
        • Natsuaki M.
        • Morimoto T.
        • Furukawa Y.
        • Nakagawa Y.
        • Kadota K.
        • Yamaji K.
        • Ando K.
        • Shizuta S.
        • Shiomi H.
        • Tada T.
        • Tazaki J.
        • Kato Y.
        • Hayano M.
        • Abe M.
        • Tamura T.
        • Shirotani M.
        • Miki S.
        • Matsuda M.
        • Takahashi M.
        • Ishii K.
        • Tanaka M.
        • Aoyama T.
        • Doi O.
        • Hattori R.
        • Kato M.
        • Suwa S.
        • Takizawa A.
        • Takatsu Y.
        • Shinoda E.
        • Eizawa H.
        • Takeda T.
        • Lee J.-D.
        • Inoko M.
        • Ogawa H.
        • Hamasaki S.
        • Horie M.
        • Nohara R.
        • Kambara H.
        • Fujiwara H.
        • Mitsudo K.
        • Nobuyoshi M.
        • Kita T.
        • Kimura T.
        Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2.
        Circ Cardiovasc Interv. 2014; 7: 168-179
        • Mauri L.
        • Hsieh W.
        • Massaro J.M.
        • Ho K.K.L.
        • D'Agostino R.
        • Cutlip D.E.
        Stent thrombosis in randomized clinical trials of drug-eluting stents.
        N Engl J Med. 2007; 356: 1020-1029
        • Serruys P.W.
        • Ong A.T.L.
        • van Herwerden L.A.
        • Sousa J.E.
        • Jatene A.
        • Bonnier J.J.R.M.
        • Schönberger J.P.
        • Buller N.
        • Bonser R.
        • Disco C.
        • Backx B.
        • Hugenholtz P.G.
        • Firth B.G.
        • Unger F.
        Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial.
        J Am Coll Cardiol. 2005; 46: 575-581
        • Tada T.
        • Natsuaki M.
        • Morimoto T.
        • Furukawa Y.
        • Nakagawa Y.
        • Byrne R.A.
        • Kastrati A.
        • Kadota K.
        • Iwabuchi M.
        • Shizuta S.
        • Tazaki J.
        • Shiomi H.
        • Abe M.
        • Ehara N.
        • Mizoguchi T.
        • Mitsuoka H.
        • Inada T.
        • Araki M.
        • Kaburagi S.
        • Taniguchi R.
        • Eizawa H.
        • Nakano A.
        • Suwa S.
        • Takizawa A.
        • Nohara R.
        • Fujiwara H.
        • Mitsudo K.
        • Nobuyoshi M.
        • Kita T.
        • Kimura T.
        Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
        Circ Cardiovasc Interv. 2012; 5: 381-391
        • Montalescot G.
        • Wiviott S.D.
        • Braunwald E.
        • Murphy S.A.
        • Gibson C.M.
        • McCabe C.H.
        • Antman E.M.
        Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
        Lancet. 2009; 373: 723-731
        • Wallentin L.
        • Becker R.C.
        • Budaj A.
        • Cannon C.P.
        • Emanuelsson H.
        • Held C.
        • Horrow J.
        • Husted S.
        • James S.
        • Katus H.
        • Mahaffey K.W.
        • Scirica B.M.
        • Skene A.
        • Steg P.G.
        • Storey R.F.
        • Harrington R.A.
        • Freij A.
        • Thorsén M.
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 361: 1045-1057
        • Stone G.W.
        • Witzenbichler B.
        • Guagliumi G.
        • Peruga J.Z.
        • Brodie B.R.
        • Dudek D.
        • Kornowski R.
        • Hartmann F.
        • Gersh B.J.
        • Pocock S.J.
        • Dangas G.
        • Wong S.C.
        • Kirtane A.J.
        • Parise H.
        • Mehran R.
        Bivalirudin during primary PCI in acute myocardial infarction.
        N Engl J Med. 2008; 358: 2218-2230
        • Hofma S.H.
        • Brouwer J.
        • Velders M.A.
        • van't Hof A.W.J.
        • Smits P.C.
        • Queré M.
        • de Vries C.J.
        • van Boven A.J.
        Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
        J Am Coll Cardiol. 2012; 60: 381-387
        • Sabate M.
        • Cequier A.
        • Iñiguez A.
        • Serra A.
        • Hernandez-Antolin R.
        • Mainar V.
        • Valgimigli M.
        • Tespili M.
        • den Heijer P.
        • Bethencourt A.
        • Vazquez N.
        • Gómez-Hospital J.A.
        • Baz J.A.
        • Martin-Yuste V.
        • van Geuns R.-J.
        • Alfonso F.
        • Bordes P.
        • Tebaldi M.
        • Masotti M.
        • Silvestro A.
        • Backx B.
        • Brugaletta S.
        • van Es G.A.
        • Serruys P.W.
        Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.
        Lancet. 2012; 380: 1482-1490
        • Valgimigli M.
        • Borghesi M.
        • Tebaldi M.
        • Vranckx P.
        • Parrinello G.
        • Ferrari R.
        Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
        Eur Heart J. 2013; 34: 909-919
        • Gwon H.-C.
        • Hahn J.-Y.
        • Park K.W.
        • Bin Song Y.
        • Chae I.-H.
        • Lim D.-S.
        • Han K.-R.
        • Choi J.-H.
        • Choi S.-H.
        • Kang H.-J.
        • Koo B.-K.
        • Ahn T.
        • Yoon J.-H.
        • Jeong M.-H.
        • Hong T.-J.
        • Chung W.-Y.
        • Choi Y.-J.
        • Hur S.-H.
        • Kwon H.-M.
        • Jeon D.-W.
        • Kim B.-O.
        • Park S.-H.
        • Lee N.-H.
        • Jeon H.-K.
        • Jang Y.
        • Kim H.-S.
        Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus versus Cypher to Reduce Late Loss after Stenting (EXCELLENT) randomized, multicenter study.
        Circulation. 2012; 125: 505-513
        • Kim B.-K.
        • Hong M.-K.
        • Shin D.-H.
        • Nam C.-M.
        • Kim J.-S.
        • Ko Y.-G.
        • Choi D.
        • Kang T.-S.
        • Park B.-E.
        • Kang W.-C.
        • Lee S.-H.
        • Yoon J.-H.
        • Hong B.-K.
        • Kwon H.-M.
        • Jang Y.
        A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet therapy following Endeavor zotarolimus-eluting stent implantation).
        J Am Coll Cardiol. 2012; 60: 1340-1348
        • Feres F.
        • Costa R.A.
        • Abizaid A.
        • Leon M.B.
        • Marin-Neto J.A.
        • Botelho R.V.
        • King S.B.
        • Negoita M.
        • Liu M.
        • de Paula J.E.T.
        • Mangione J.A.
        • Meireles G.X.
        • Castello H.J.
        • Nicolela E.L.
        • Perin M.A.
        • Devito F.S.
        • Labrunie A.
        • Salvadori D.
        • Gusmão M.
        • Staico R.
        • Costa J.R.
        • de Castro J.P.
        • Abizaid A.S.
        • Bhatt D.L.
        Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
        JAMA. 2013; 310: 2510-2522
        • Colombo A.
        • Chieffo A.
        • Frasheri A.
        • Garbo R.
        • Masotti-Centol M.
        • Salvatella N.
        • Oteo Dominguez J.F.
        • Steffanon L.
        • Tarantini G.
        • Presbitero P.
        • Menozzi A.
        • Pucci E.
        • Mauri J.
        • Cesana B.M.
        • Giustino G.
        • Sardella G.
        Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.
        J Am Coll Cardiol. 2014; 64: 2086-2097
        • Gilard M.
        • Barragan P.
        • Noryani A.A.L.
        • Noor H.A.
        • Majwal T.
        • Hovasse T.
        • Castellant P.
        • Schneeberger M.
        • Maillard L.
        • Bressolette E.
        • Wojcik J.
        • Delarche N.
        • Blanchard D.
        • Jouve B.
        • Ormezzano O.
        • Paganelli F.
        • Levy G.
        • Sainsous J.
        • Carrie D.
        • Furber A.
        • Berland J.
        • Darremont O.
        • Le Breton H.
        • Lyuycx-Bore A.
        • Gommeaux A.
        • Cassat C.
        • Kermarrec A.
        • Cazaux P.
        • Druelles P.
        • Dauphin R.
        • Armengaud J.
        • Dupouy P.
        • Champagnac D.
        • Ohlmann P.
        • Endresen K.
        • Benamer H.
        • Kiss R.G.
        • Ungi I.
        • Boschat J.
        • Morice M.-C.
        6- versus 24-Month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
        J Am Coll Cardiol. 2015; 65: 777-786
        • Mauri L.
        • Kereiakes D.J.
        • Yeh R.W.
        • Driscoll-Shempp P.
        • Cutlip D.E.
        • Steg P.G.
        • Normand S.-L.T.
        • Braunwald E.
        • Wiviott S.D.
        • Cohen D.J.
        • Holmes D.R.
        • Krucoff M.W.
        • Hermiller J.
        • Dauerman H.L.
        • Simon D.I.
        • Kandzari D.E.
        • Garratt K.N.
        • Lee D.P.
        • Pow T.K.
        • Lee P.V.
        • Rinaldi M.J.
        • Massaro J.M.
        Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
        N Engl J Med. 2014; 371: 2155-2166
        • Hirsch A.
        • Verouden N.J.W.
        • Koch K.T.
        • Baan J.
        • Henriques J.P.S.
        • Piek J.J.
        • Rohling W.J.
        • van der Schaaf R.J.
        • Tijssen J.G.P.
        • Vis M.M.
        • de Winter R.J.
        Comparison of long-term mortality after percutaneous coronary intervention in patients treated for acute ST-elevation myocardial infarction versus those with unstable and stable angina pectoris.
        Am J Cardiol. 2009; 104: 333-337
        • Kawaguchi R.
        • Kimura T.
        • Morimoto T.
        • Oshima S.
        • Hoshizaki H.
        • Kawai K.
        • Shiode N.
        • Hiasa Y.
        • Mitsudo K.
        Safety and efficacy of sirolimus-eluting stent implantation in patients with acute coronary syndrome in the real world.
        Am J Cardiol. 2010; 106: 1550-1560
        • Wald D.S.
        • Morris J.K.
        • Wald N.J.
        • Chase A.J.
        • Edwards R.J.
        • Hughes L.O.
        • Berry C.
        • Oldroyd K.G.
        Randomized trial of preventive angioplasty in myocardial infarction.
        N Engl J Med. 2013; 369: 1115-1123